Tom Robinson, vice president of global access at JDRF, talks about the data collection process in creating the Type 1 Diabetes (T1D) Index.
Tom Robinson, vice president of global access at JDRF, talks about the data collection process in creating the Type 1 Diabetes (T1D) Index.
Transcript
How did you ensure the data being used to create the T1D Index were accurate and representative?
We were fortunate in that we had partners coming in who've done a lot of foundational work in the past. For our incidence data, for example, the IDF Atlas has been collecting and vetting good quality incident studies for 20 years. So we went back and took all 20 years worth of incidence studies, it took us all the way back to the 1930s, but we knew that they had all passed community review and academic muster. For mortality studies, again, there have been a few studies that looked at mortality rates and tried to predict what they might be using regression models. And we said, okay, well we could take those studies, let's generalize them to an adult group—they had looked in pediatric populations—let's take them into an adult group as well, and then let's, instead of using kind of a traditional regression model, let's use a random forest regression model using all the latest machine learning technology and cross-validation—all these things that are possible.
So the new model was far more powerfully predictive than the previous one, but we couldn't have done it without the previous one as a foundation. So constantly what we've been doing is taking really great work that epidemiologists have been doing, updating it a little bit and expanding it with the latest techniques or the latest data or the latest studies and then stitching it all together into 1 super model. That's essentially how we made sure that we were using good information, standing on the shoulders of giants, that kind of thing.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More